Danske Bank A S Has $90.05 Million Holdings in Stryker Corporation $SYK

Danske Bank A S increased its holdings in shares of Stryker Corporation (NYSE:SYK) by 17.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 256,206 shares of the medical technology company’s stock after buying an additional 38,780 shares during the quarter. Danske Bank A S’s holdings in Stryker were worth $90,049,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in SYK. United Financial Planning Group LLC acquired a new stake in Stryker during the 3rd quarter worth $27,000. Strive Asset Management LLC acquired a new stake in Stryker during the 3rd quarter worth $30,000. ANTIPODES PARTNERS Ltd acquired a new stake in Stryker during the 3rd quarter worth $34,000. Copia Wealth Management raised its stake in Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock worth $40,000 after buying an additional 69 shares during the period. Finally, Ares Financial Consulting LLC acquired a new stake in Stryker during the 4th quarter worth $40,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

SYK opened at $314.64 on Friday. The business’s 50-day moving average price is $345.67 and its two-hundred day moving average price is $356.95. Stryker Corporation has a 1 year low of $311.31 and a 1 year high of $404.87. The company has a market capitalization of $120.50 billion, a price-to-earnings ratio of 37.46, a P/E/G ratio of 1.84 and a beta of 0.92. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts expect that Stryker Corporation will post 14.91 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Investors of record on Tuesday, March 31st were given a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is currently 41.90%.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Strong cash flow and profitability expansion — Reported net income, operating profit and cash from operations rose materially year-over-year (cash from ops jumped sharply), supporting balance-sheet strength and capital spending. Quiver Quantitative: Q1 results
• Positive Sentiment: Company maintained FY‑2026 EPS guidance (14.900–15.100), signaling management confidence in full‑year recovery despite the soft quarter. Reuters: misses estimates, maintains outlook
• Neutral Sentiment: Company highlighted quick operational recovery from a recent cyber incident; management framed the issue as contained and service delivery resumed. WSJ: cyberattack recovery
• Neutral Sentiment: Ongoing commercial wins and government contract awards provide recurring revenue tailwinds, but these are modest relative to total sales. Quiver: gov’t contracts & institutional activity
• Negative Sentiment: Earnings and revenue missed consensus — Q1 adjusted EPS missed estimates and revenue growth was only ~2.6%, below Street expectations, driving the initial negative market reaction. Zacks: EPS & revenue lag
• Negative Sentiment: Demand weakness in implants and complex-procedure devices weighed on results and led to a contraction in adjusted operating margin (down ~180 bps) and lower adjusted EPS versus prior year. GlobeNewswire: operating results & margin details
• Negative Sentiment: Insider and large institutional selling noted in filings and data feeds, which can add downward pressure on the stock in the near term. Quiver: insider & hedge fund activity

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. William Blair reaffirmed an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. Jefferies Financial Group reissued a “buy” rating and issued a $465.00 price target on shares of Stryker in a research note on Wednesday, March 4th. The Goldman Sachs Group dropped their price target on Stryker from $403.00 to $357.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Finally, Raymond James Financial raised Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target on the stock in a research note on Tuesday, January 6th. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $421.11.

Insider Activity

In related news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.